Back to Search Start Over

ISG15/GRAIL1/CD3 axis influences survival of patients with esophageal adenocarcinoma.

Authors :
McEwen DP
Ray P
Nancarrow DJ
Wang Z
Kasturirangan S
Abdullah S
Balan A
Hoskeri R
Thomas D
Lawrence TS
Beer DG
Lagisetty KH
Ray D
Source :
JCI insight [JCI Insight] 2024 May 23; Vol. 9 (13). Date of Electronic Publication: 2024 May 23.
Publication Year :
2024

Abstract

Immunosuppression is a common feature of esophageal adenocarcinoma (EAC) and has been linked to poor overall survival (OS). We hypothesized that upstream factors might negatively influence CD3 levels and T cell activity, thus promoting immunosuppression and worse survival. We used clinical data and patient samples of those who progressed from Barrett's to dysplasia to EAC, investigated gene (RNA-Seq) and protein (tissue microarray) expression, and performed cell biology studies to delineate a pathway impacting CD3 protein stability that might influence EAC outcome. We showed that the loss of both CD3-ε expression and CD3+ T cell number correlated with worse OS in EAC. The gene related to anergy in lymphocytes isoform 1 (GRAIL1), which is the prominent isoform in EACs, degraded (ε, γ, δ) CD3s and inactivated T cells. In contrast, isoform 2 (GRAIL2), which is reduced in EACs, stabilized CD3s. Further, GRAIL1-mediated CD3 degradation was facilitated by interferon-stimulated gene 15 (ISG15), a ubiquitin-like protein. Consequently, the overexpression of a ligase-dead GRAIL1, ISG15 knockdown, or the overexpression of a conjugation-defective ISG15-leucine-arginine-glycine-glycine mutant could increase CD3 levels. Together, we identified an ISG15/GRAIL1/mutant p53 amplification loop negatively influencing CD3 levels and T cell activity, thus promoting immunosuppression in EAC.

Details

Language :
English
ISSN :
2379-3708
Volume :
9
Issue :
13
Database :
MEDLINE
Journal :
JCI insight
Publication Type :
Academic Journal
Accession number :
38781019
Full Text :
https://doi.org/10.1172/jci.insight.179315